Stratta R J, Gaber A O, Shokouh-Amiri M H, Reddy K S, Alloway R R, Egidi M F, Grewal H P, Gaber L W, Hathaway D
Department of Surgery, University of Tennessee, Memphis 38163-2116, USA.
Ann Surg. 1999 May;229(5):701-8; discussion 709-12. doi: 10.1097/00000658-199905000-00013.
To report initial experience with the combination of a novel technique of portal-enteric pancreas transplantation with newer immunosuppressive strategies that eliminate antilymphocyte induction therapy.
A new surgical technique of pancreas transplantation has been developed with portal venous delivery of insulin and enteric drainage of the exocrine secretions (portal-enteric). The introduction of potent immunosuppressive agents may allow simultaneous kidney and pancreas transplants (SKPT) to be performed without antilymphocyte induction.
From September 1996 to November 1998, the authors performed 28 primary SKPTs with portal-enteric drainage and no antilymphocyte induction. All patients received triple immunosuppression with tacrolimus, mycophenolate mofetil, and steroids. The study group had a mean age of 38 years and a mean preoperative duration of diabetes of 25 years. Four patients (14%) had prior kidney transplants.
All patients had immediate renal allograft function. Actual patient, kidney, and pancreas graft survival rates were 86%, 82%, and 82%, respectively, after a mean follow-up of 12 months. Four patients died, three as a result of cardiac events unrelated to SKPT. Five kidney and five pancreas grafts were lost, including five deaths with function and three cases of chronic rejection. The mean length of stay and total charges for the initial hospital stay were 12.5 days and $99,517. The mean number of readmissions was 2.9, and 10 patients (36%) had no readmissions. Six patients (21 %) developed acute rejection, with five (18%) receiving antilymphocyte therapy. Seven patients (25%) underwent relaparotomy, including two (7%) for intraabdominal infection. Nine patients (32%) had major infections, including three (11%) with cytomegaloviral infection. Of the 24 surviving patients, 22 (92%) are both dialysis- and insulin-free.
These preliminary results suggest that SKPT with portal-enteric drainage without antilymphocyte induction can be performed with excellent outcomes.
报告门静脉-肠道胰腺移植新技术与消除抗淋巴细胞诱导治疗的新型免疫抑制策略相结合的初步经验。
已开发出一种新的胰腺移植手术技术,即通过门静脉输送胰岛素并经肠道引流外分泌液(门静脉-肠道)。强效免疫抑制剂的引入可能使同期肾胰联合移植(SKPT)无需抗淋巴细胞诱导即可进行。
1996年9月至1998年11月,作者进行了28例采用门静脉-肠道引流且无抗淋巴细胞诱导的原发性SKPT。所有患者均接受他克莫司、霉酚酸酯和类固醇的三联免疫抑制治疗。研究组患者平均年龄38岁,术前糖尿病平均病程25年。4例患者(14%)曾接受过肾移植。
所有患者的肾移植立即发挥功能。平均随访12个月后,实际患者、肾和胰腺移植存活率分别为86%、82%和82%。4例患者死亡,3例死于与SKPT无关的心脏事件。5例肾移植和5例胰腺移植失败,包括5例有功能的死亡病例和3例慢性排斥反应病例。首次住院的平均住院时间和总费用分别为12.5天和99517美元。再次入院的平均次数为2.9次,10例患者(36%)未再次入院。6例患者(21%)发生急性排斥反应,5例(18%)接受抗淋巴细胞治疗。7例患者(25%)接受再次剖腹手术,其中2例(7%)因腹腔内感染。9例患者(32%)发生严重感染,包括3例(11%)巨细胞病毒感染。在24例存活患者中,22例(92%)不再需要透析和胰岛素治疗。
这些初步结果表明,无需抗淋巴细胞诱导的门静脉-肠道引流SKPT可取得优异的效果。